Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
$7.58
+0.1%
$7.71
$6.60
$14.60
$1.79B1.559,375 shs665 shs
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
$0.83
-8.1%
$1.37
$0.73
$11.18
$11.48M3.7604,785 shs460,713 shs
Moderna, Inc. stock logo
MRNA
Moderna
$24.72
-1.9%
$31.10
$23.15
$170.47
$9.56B2.237.25 million shs6.68 million shs
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$5.99
+1.2%
$5.75
$4.95
$12.83
$427.91M1.03776,937 shs580,386 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
+0.46%+6.62%-6.20%-15.37%+6.01%
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
+6.09%-13.23%-39.84%-59.71%-43.60%
Moderna, Inc. stock logo
MRNA
Moderna
-4.00%-5.55%-27.43%-25.39%-75.73%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
-1.99%-2.79%+5.15%-5.13%-33.71%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/AN/AN/AN/AN/AN/AN/AN/A
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
2.4689 of 5 stars
3.62.00.00.01.81.71.3
Moderna, Inc. stock logo
MRNA
Moderna
4.2492 of 5 stars
4.01.00.04.62.22.51.3
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
2.0719 of 5 stars
0.01.00.00.04.10.83.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
0.00
N/AN/AN/A
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
3.29
Buy$12.901,455.15% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$58.70137.51% Upside
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest GOVX, SIGA, MRNA, and BVNRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/16/2025
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/15/2025
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $8.50
4/10/2025
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
4/9/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$39.00 ➝ $32.00
3/28/2025
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
2/27/2025
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
(Data available from 4/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
$1.02B1.75$1.82 per share4.17$6.41 per share1.18
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
$3.95M2.90N/AN/A$3.24 per share0.26
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B2.99N/AN/A$28.33 per share0.87
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$138.72M3.08$0.94 per share6.34$2.77 per share2.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
$214.20M$0.6010.997.22N/A18.33%10.65%7.90%5/14/2025 (Estimated)
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
-$25.97M-$5.67N/AN/AN/AN/A-809.87%-349.34%5/13/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
$68.07M$0.824.994.79N/A49.33%49.06%38.72%5/6/2025 (Estimated)

Latest GOVX, SIGA, MRNA, and BVNRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
-$0.51N/AN/AN/A$1.75 millionN/A
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.90N/AN/AN/A$130.35 millionN/A
3/27/2025Q4 2024
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
-$0.79-$0.30+$0.49-$0.30$2.38 million$3.00 million
3/11/2025Q4 2024
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/A$0.63N/A$0.63N/A$81.40 million
3/5/2025Q4 2024
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
$0.40$0.47+$0.07$0.47$264.06 million$299.48 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/AN/AN/AN/AN/A
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/AN/AN/AN/AN/A

Latest GOVX, SIGA, MRNA, and BVNRY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/8/2025
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
special$0.604/29/20254/29/20255/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/A
1.69
0.98
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
N/A
4.17
4.17
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
N/A
8.10
5.32

Institutional Ownership

CompanyInstitutional Ownership
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/A
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
6.09%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
55.40%

Insider Ownership

CompanyInsider Ownership
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/A
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
5.70%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
1.54%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
1,379236.50 millionN/ANot Optionable
GeoVax Labs, Inc. stock logo
GOVX
GeoVax Labs
1013.84 million8.90 millionNot Optionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
SIGA Technologies, Inc. stock logo
SIGA
SIGA Technologies
4071.44 million70.31 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bavarian Nordic A/S stock logo

Bavarian Nordic A/S OTCMKTS:BVNRY

$7.58 +0.01 (+0.13%)
As of 03:22 PM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

GeoVax Labs stock logo

GeoVax Labs NASDAQ:GOVX

$0.83 -0.07 (-8.08%)
As of 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Moderna stock logo

Moderna NASDAQ:MRNA

$24.72 -0.48 (-1.89%)
Closing price 03:59 PM Eastern
Extended Trading
$24.68 -0.04 (-0.14%)
As of 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

SIGA Technologies stock logo

SIGA Technologies NASDAQ:SIGA

$5.99 +0.07 (+1.18%)
Closing price 04:00 PM Eastern
Extended Trading
$5.99 0.00 (0.00%)
As of 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.